Korean J Dermatol.
2018 Dec;56(10):581-593.
Treatment of Atopic Dermatitis
- Affiliations
-
- 1Department of Dermatology, College of Medicine, Eulji University, Daejeon, Korea.
- 2Department of Dermatology, College of Medicine, Chosun University, Gwangju, Korea.
- 3Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- 4Department of Dermatology, College of Medicine, Hallym University, Chuncheon, Korea.
- 5Department of Dermatology, College of Medicine, Yonsei University, Seoul, Korea.
- 6Department of Dermatology, College of Medicine, Chungnam University, Daejeon, Korea.
- 7Department of Dermatology, College of Medicine, Korea University, Seoul, Korea.
- 8Department of Dermatology, College of Medicine, Kyunghee University, Seoul, Korea. bellotte@hanmail.net
- 9Department of Dermatology, National Medical Center, Seoul, Korea.
- 10Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea.
- 11Department of Dermatology, School of Medicine, Kyungpook National University, Daegu, Korea.
- 12Department of Dermatology, College of Medicine, Soonchunhyang University11, Cheonan, Korea. ylpark@schmc.ac.kr
Abstract
- Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that affects both children and adults. AD is the cause of considerable morbidity including severe pruritus and impaired quality of life. Treatments for active disease include avoidance of triggering factors, barrier repair, topical medications including topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs), phototherapy, antibacterial agents, and systemic immunosuppressants including cyclosporine. Until recently, the only Food and Drug Administration (FDA)-approved systemic treatment options for patients with moderate-to-severe AD were steroids and cyclosporine. Systemic steroids are not recommended by current guidelines and are commonly associated with disease rebound. Instead, clinicians choose from several off-label immunosuppressants. In 2018, the Korean FDA approved dupilumab for adults with moderate-to-severe AD whose disease is not adequately controlled with topical therapies. The implementation of treatment guidelines for AD is challenging. Herein, we review the several treatment modalities for AD and recommend a treatment algorithm.
Keyword
MeSH Terms
-
Adrenal Cortex Hormones
Adult
Anti-Bacterial Agents
Calcineurin Inhibitors
Child
Cyclosporine
Dermatitis, Atopic*
Humans
Immunosuppressive Agents
Phototherapy
Pruritus
Quality of Life
Skin Diseases
Steroids
United States Food and Drug Administration
Adrenal Cortex Hormones
Anti-Bacterial Agents
Calcineurin Inhibitors
Cyclosporine
Immunosuppressive Agents
Steroids
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Measurement of Atopic Dermatitis Disability
- Serum IgE Level in Patients of Atopic Dermatitis and Atopic Dermatitis with Molluscum Contagiosum
- Atopic dermatitis
- Nipple Involvement in Atopic Dermatitis: Report of 3 cases
- Two Cases of Atopic Dermatitis Developing Ocular Complication and Immunological Disturbance
